论文部分内容阅读
目的 :观察不同剂量米非司酮治疗子宫肌瘤的临床效果。方法 :选择医院2013年8月~2014年8月收治的子宫肌瘤患者120例,随机分为实验组和对照组,各60例,实验组患者采用米非司酮12.5mg治疗,对照组患者采用25mg治疗,治疗3个月,观察两组患者治疗前后子宫肌瘤体积变化情况及患者服药后的不良反应情况。结果 :治疗前,两组患者子宫肌瘤体积比较差异无统计学意义,两组患者用药后不良反应发生率比较差异无统计学意义(P>0.05);服药3个月之后,两组患者子宫肌瘤体积均小于治疗前,且实验组患者子宫肌瘤体积小于对照组,比较差异具有统计学意义(P<0.05)。结论 :采用12.5mg和25mg米非司酮治疗子宫肌瘤患者时,均可缩小子宫肌瘤体积,但小剂量米非司酮治疗时缩小效果更佳。
Objective: To observe the clinical efficacy of different doses of mifepristone in the treatment of uterine fibroids. Methods: A total of 120 patients with uterine leiomyoma admitted from August 2013 to August 2014 in our hospital were randomly divided into experimental group and control group, 60 cases in each group. The patients in experimental group were treated with 12.5 mg mifepristone and the control group Using 25mg treatment, treatment for 3 months, observe the volume changes of uterine fibroids in both groups before and after treatment and the adverse reactions of patients after taking the drug. Results: Before treatment, there was no significant difference in the volume of uterine fibroids between the two groups. There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). After three months, the uterine fibroids Fibroids volume less than before treatment, and the experimental group of patients with uterine fibroids volume is smaller than the control group, the difference was statistically significant (P <0.05). Conclusion: The treatment of uterine fibroids with 12.5mg and 25mg mifepristone patients, can reduce the size of uterine fibroids, but the effect of smaller doses of mifepristone to reduce the better.